Aleglitazar

Generic Name
Aleglitazar
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C24H23NO5S
CAS Number
475479-34-6
Unique Ingredient Identifier
41T4OAG59U
Background

Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes. In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects and toxicity.

Indication

Investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: aleglitazar
Drug: rifampicin
First Posted Date
2012-09-06
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
24
Registration Number
NCT01679639

A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers

First Posted Date
2012-06-08
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
18
Registration Number
NCT01615354

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

First Posted Date
2011-07-20
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
55
Registration Number
NCT01398267

A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: aleglitazar
First Posted Date
2010-09-09
Last Posted Date
2015-12-24
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
38
Registration Number
NCT01197911

A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers

First Posted Date
2010-08-25
Last Posted Date
2012-05-22
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
44
Registration Number
NCT01188317

A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers

First Posted Date
2010-08-25
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
44
Registration Number
NCT01188304

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Phase 3
Completed
Conditions
Diabetes Mellitus Type 2
Interventions
Drug: Placebo
Drug: Aleglitazar
First Posted Date
2010-01-06
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
7226
Registration Number
NCT01042769

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

First Posted Date
2010-01-06
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
302
Registration Number
NCT01043029

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.

Phase 2
Completed
Conditions
Diabetes Mellitus Type 2
Interventions
Drug: Actos
Drug: aleglitazar
First Posted Date
2007-04-17
Last Posted Date
2016-08-05
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
14
Registration Number
NCT00461058

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Phase 2
Completed
Conditions
Diabetes Mellitus Type 2
Interventions
Drug: Actos
Drug: aleglitazar
First Posted Date
2007-04-17
Last Posted Date
2016-08-01
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
176
Registration Number
NCT00461006
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy